Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression

Neuropsychobiology

Volumn 35, Issue 3, 1997, Pages 123-127

  Sluzewska, A ^a   Sobieska, M ^a   Rybakowski, A K ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Acute phase proteins; Alpha 1 antichymotrypsin; Alpha 1 acid glycoprotein; Lithium potentiation of antidepressants

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 1 ANTICHYMOTRYPSIN; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; C REACTIVE PROTEIN; CLOMIPRAMINE; DIBENZEPIN; FLUOXETINE; GLYCOPROTEIN; IMIPRAMINE; LITHIUM; MOCLOBEMIDE; SERTRALINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG POTENTIATION; FEMALE; GLYCOSYLATION; HUMAN; IMMUNE RESPONSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0030902033     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000119332     Document Type: Article

References (36)

1. De Montigny C, Grundberg F, Mayer A, Desehenes JP: Lithium induces rapid relief of depression in tricyclic antidepressant drug nonresponders. Br J Psychiatry 1981:138:252-256.
2. Katona CLE, Abou-Salch MT, Harrison DA et al: Placebo-controled trial of lithium augmentation of fluoxentincandlofepraminc. Br J Psychiatry 1995;166:80-86.
3. Rybakowski JK, Matkowski K: Adding lithium to antidepressant therapy: Factors related to therapeutic potentiation. Eur Neuropsycho-pharmacol 1992;2:161-165.
4. De Montigny C: Lithium addition in refractory depression: in Nolen WA, Zohar J, Roose SP. Amsterdam JD (eds): Refractory Depression: Current Strategies and Future Directions. New York. Wilcv. 1994. pp 47-57.
5. Blier P, De Montigny C: Short-term lithium administration enhances scrotoninergic neurotransmission: Electrophysiological evidence in the rat CNS. Eur J Pharmacol 1985; 113:66-77.
6. Treiser SL, Cascio CS, O'Donohue TL, Kellar K: Lithium increases serotonin release and decreases serotonin receptors in hippocampus. Science 1981;213:1529-1531.
7. Macs M, Sharpe S, Bosmans E, Vandenwoude M, Suy E, Uyltenbroeck W, Cooreman W, Vandervorst C, Raus J: Disturbances in acute phase proteins during melancholia; additional evidence for the presence of an inflammatory process during that illness. Prog Neuropsvcho-pharmacol Biol Psychiatry 1992;16:501-515.
8. Sluzewska A, Rybakowski JK, Bosmans E, Maes M, Sobieska M: Some interleukins, their receptors and alpha-1-acid glycoprotein as the indicators of immune activation in depression. Behav Pharmacol 1995;6(1);66-68.
9. Nemeroff ChB, Krisnam RR, Blazer DG, Knight DL, Benjamin D, Meyerson JR: Elevated plasma concentration of alpha-1-acid glycoprotein, a putative endogenous inhibitor of tritated imipramine binding site in depressed patients. Arch Gen Psychiatry 1990; 47:337-340.
10. Healy D, Calvinj J, Whitehouse AM, White W, Wilton-Cox H, Theodorou AE, Lawrence KM. Horton RW. Paykel ES: Alpha- 1-acid glycoprotein in major depressives and eating disorders. J Affective Disord 1991;22:13-20.
11. Joyce PR, Hawes CR, Mudler RT: Elevated levels of acute phase proteins in major depression. Biol Psychiatry 1992:32:1035-1041.
12. Maes M: Acute phase protein alterations in major depression: A review. Rev Neurosci 1993:4:407-416.
13. 1-antitrypsin. haptoglobin and ceruloplasmin and lower retinol binding protein plasma levels in major depressed subjects. J Affective Disord 1992:24:183-192.
14. Sluzewska A, Rybakowski JK, Sobieska M, Wiktorowiez K: Concentration and microhetc-rogeneity glycophorms of alpha-l-acid glycoprotein in major depressive disorder. J Affective Disord 1996;39:149-155.
15. Song C, Dinan T, Leonard BE: Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J Affective Disord 1994:30: 283-288.
16. Macs M, Vandewoude M, Scharpe S, De Clerk L, Stevens W, Lepoutre L: Anthropometric and biochemical assessment of nutritional state in depression: Evidence for lower visceral protein plasma levels in depression. J Affective Disord 1991;23:25-33.
17. Maes M, Meltzer HY, Buckley P, Bosmans E: Plasma soluble interleukin-2 and trensferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci 1995:244: 325-329.
18. Swartz CM: Albumine decrement in depression and cholesterol decrement in mania. J Affective Disord 1990;19:173-176.
19. Sluzewska A, Rybakowski JK, Laciak K, Mackiewiez A, Sobieska M, Wiktorowiez K: Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann NY Acad Sci 1995;762:474-477.
20. Abraham KI, Ieni JR, Meyerson LR: Purification and properties of human plasma endogenous modulator for platelet tricyclic binding/serotonine transport complex. Biochim Bio-physActa 1987;923:8-21.
21. Kremer JMH, Wilting J, Janssen LHM, Drug binding to human alpha-l-acid glycoprotein in health and disease. Pharmacol Rev 1988:40:1-47.
22. Turner GA: N-Glycosylation of serum proteins in disease and its investigation using lectins. Clin Chint Acta 1992:208:149-171.
23. Durand G: Glycan variations of human alpha-l-acid glycoprotein modulate the biology of macrophages. Prog Clin Biol Res 1989:300: 247-252.
24. Pos O, Ostendorp RAJ, Van der Stely ME, Scheper RJ, Van Dijk W: Con A-nonrcactivc human alpha-1-acid glycoprotein (AGP) is more effective in modulation of lymphocyte proliferation than Con A-reactive serum variants. Inflammation 1990;14:133-141.
25. Kushner I, Mackiewiez A: The acute phase response: An overview: in Mackiewicz A, Kushner I, Baumann H (eds): Acute Phase Proteins. Molecular Biology, Biochemistry and Clinical Applications. Boca Raton. CRC. 1993. pp 3-19.
26. Sluzewska A, Rybakowski JK, Sobieska M, Bosmans E, Pollet H, Wiktorowicz K: Increased levels of alpha-1 -acid glycoprotein and interleukin-6 in refractory depression. Depression 1995:3:170-175.
27. Sluzewska A, Rybakowski JK, Sobieska M, Wiktorowiez K: The effect of lithium, carba-mazepinc and fluoxetine on alpha-l-acid glycoprotein and alpha-l-antichymotrypsin in depressed patients. Neuropsychopharmacology 1994:10(3S):202.
28. Laurell CB: Quantitative estimation of proteins by electrophoresis in agarose gel-containing antibodies. Ann Biochcm 1966;15:45-52.
29. Bog-Hansen TC: Crossed immuno-affinoelec-trophoresis: An analytical method to predict the results of affinity chromatography. Ann Biochem 1973:56:480-488.
30. Mackiewiez A, Mackiewiez S: Determination of lectin-sugar dissociation contents by agarose affinity electrophoresis. Arch Gen Psychiatry 1986:56:480-484.
31. Austin M-PV, Souza FGM, Goodwin GM: Lithium augmentation in antidepressant-resistant patients: Quantitative analysis. Br J Psychiatry 1991;159:510-514.
32. Sluzewska A, Nowakowska E, Gryska K, Mackiewicz A: Haptoglobin levels in chronic mild stress model of depression in rats before and after treatment. Eur Neuropsychopharma-col 1994:4:302.
33. Sluzewska A, Rybakowski JK, Bosmans E, Maes M, Behrmans R, Pollet H: The effect of treatment with lithium and carbamazepine on some interleukines and their receptors in depressed patients. Pharmacol Res 1995:3:366.
34. Pawlowski T, Mackiewiez S, Mackiewiez A: Microheterogeneity of alpha-1 acid glycoprotein in detection of intercurrent infection in rheumatoid arthritis. Arthritis Rheum 1989; 32:347-351.
35. Van Dijk W, Turner GA, Mackiewiez A: Changes in glycosylation of acute phase proteins in health and disease: occurrence, regulation and function. Glycosylation Dis 1994; 1:5-14.
36. Sluzewska A, Rybakowski JK: Cortisol levels and immunological indices in depression. Neuropsychopharmacology 1993;9:107S.